Recombinant Pichinde viral vector expressing tuberculosis antigens elicits strong T cell responses and protection in mice.
Mtb mouse model
Pichinde virus vector
T cell immunity
T cell vaccines
tuberculosis vaccine
vaccine immunity
viral vector based vaccines
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
12
2022
accepted:
30
01
2023
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Tuberculosis (TB) caused by Using this tri-segmented PICV vector (rP18tri), we have generated viral vectored TB vaccines (TBvac-1, TBvac-2, and TBvac-10) encoding several known TB immunogens (Ag85B, EsxH, and ESAT-6/EsxA). A P2A linker sequence was used to allow for the expression of two proteins from one open-reading-frame (ORF) on the viral RNA segments. The immunogenicity of TBvac-2 and TBvac-10 and the protective efficacy of TBvac-1 and TBvac-2 were evaluated in mice. Both viral vectored vaccines elicited strong antigen-specific CD4 and CD8 T cells through intramuscular (IM) and intranasal (IN) routes as evaluated by MHC-I and MHC-II tetramer analyses, respectively. The IN inoculation route helped to elicit strong lung T cell responses. The vaccine-induced antigen-specific CD4 T cells are functional, expressing multiple cytokines as detected by intracellular cytokine staining. Finally, immunization with TBvac-1 or TBvac-2, both expressing the same trivalent antigens (Ag85B, EsxH, ESAT6/EsxA), reduced The novel PICV vector-based TB vaccine candidates can express more than two antigens
Identifiants
pubmed: 36845108
doi: 10.3389/fimmu.2023.1127515
pmc: PMC9945092
doi:
Substances chimiques
Antigens, Bacterial
0
Antigens, Viral
0
Bacterial Proteins
0
Cytokines
0
Tuberculosis Vaccines
0
Vaccines, Synthetic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1127515Informations de copyright
Copyright © 2023 Kirk, Huang, Vrba, Rahman, Block, Murphy, White, Namugenyi, Ly, Tischler and Liang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
J Immunol. 2017 Oct 1;199(7):2555-2569
pubmed: 28827285
Nat Med. 2018 Feb;24(2):130-143
pubmed: 29334373
J Exp Med. 2001 Feb 5;193(3):271-80
pubmed: 11157048
Methods Mol Biol. 2017;1581:169-179
pubmed: 28374249
Front Immunol. 2019 May 03;10:992
pubmed: 31130965
Vaccines (Basel). 2020 Nov 13;8(4):
pubmed: 33202961
mBio. 2016 Nov 22;7(6):
pubmed: 27879332
PLoS One. 2013 Dec 12;8(12):e80579
pubmed: 24349004
Mucosal Immunol. 2022 Mar;15(3):379-388
pubmed: 34671115
J Leukoc Biol. 2014 Feb;95(2):215-24
pubmed: 24006506
J Virol. 2015 Dec 16;90(5):2551-60
pubmed: 26676795
Mucosal Immunol. 2018 Nov;11(6):1743-1752
pubmed: 30115996
Cold Spring Harb Perspect Med. 2014 Jun 02;4(6):
pubmed: 24890836
J Immunol. 2011 Dec 1;187(11):5510-4
pubmed: 22058417
J Immunol. 2013 Jun 15;190(12):6311-9
pubmed: 23677471
J Virol. 2009 Jul;83(13):6357-62
pubmed: 19386714
Lancet Infect Dis. 2014 Oct;14(10):939-46
pubmed: 25151225
NPJ Vaccines. 2020 May 14;5(1):39
pubmed: 32435513
PLoS One. 2015 Nov 24;10(11):e0143552
pubmed: 26599077
Annu Rev Immunol. 2013;31:475-527
pubmed: 23516984
J Immunol. 2008 Dec 1;181(11):7948-57
pubmed: 19017986
J Gen Virol. 2016 Apr;97(4):839-843
pubmed: 26781134
J Virol. 2007 Nov;81(21):12071-6
pubmed: 17728221
J Immunol. 2014 Sep 15;193(6):2911-8
pubmed: 25086172
Am J Trop Med Hyg. 1971 Jul;20(4):631-41
pubmed: 4998616
J Immunol. 2021 Mar 1;206(5):931-935
pubmed: 33441437
J Immunol. 2014 Apr 1;192(7):2965-9
pubmed: 24591367
Front Immunol. 2020 May 19;11:909
pubmed: 32508823
Mol Ther. 2017 May 3;25(5):1222-1233
pubmed: 28342639
Nature. 2020 Jan;577(7788):95-102
pubmed: 31894150
Nat Commun. 2015 Oct 13;6:8533
pubmed: 26460802
Infect Immun. 2015 Dec 28;84(3):735-46
pubmed: 26712204
Annu Rev Immunol. 2019 Apr 26;37:521-546
pubmed: 30726153
JCI Insight. 2022 Feb 8;7(3):
pubmed: 34990408
Clin Infect Dis. 2014 Feb;58(4):470-80
pubmed: 24336911
PLoS Pathog. 2013 Jan;9(1):e1003130
pubmed: 23358848
Cell Host Microbe. 2017 Jun 14;21(6):695-706.e5
pubmed: 28618268
J Immunol. 2009 Jun 15;182(12):8047-55
pubmed: 19494330
Curr Protoc Immunol. 2011 Aug;Chapter 19:Unit19.5
pubmed: 21809318
J Immunol. 2014 Sep 1;193(5):2306-16
pubmed: 25070842
N Engl J Med. 2019 Dec 19;381(25):2429-2439
pubmed: 31661198
Nat Protoc. 2014 Jan;9(1):209-22
pubmed: 24385150
Nat Med. 2019 Feb;25(2):255-262
pubmed: 30664782
J Gen Virol. 2001 May;82(Pt 5):1013-1025
pubmed: 11297676
Nat Med. 2007 Jul;13(7):843-50
pubmed: 17558415
PLoS One. 2009 Jun 10;4(6):e5856
pubmed: 19516906
Sci Transl Med. 2010 Oct 13;2(53):53ra74
pubmed: 20944089
J Exp Med. 1983 Jul 1;158(1):74-83
pubmed: 6602861
Methods Mol Biol. 2018;1604:247-253
pubmed: 28986840
J Immunol. 2020 May 1;204(9):2331-2336
pubmed: 32229539
Nat Med. 2011 Feb;17(2):189-94
pubmed: 21258338